Abstract
As the use of immune checkpoint inhibitors (ICPi) such as pembrolizumab is rapidly expanding in the field of immuno-oncology, it is crucial for healthcare providers to be aware of their immune-related adverse effects (irAE) which are thought to be driven by augmented immune response of T-cells. While neurologic immune-related adverse events (irAE) are underrepresented in literature, their consequences could lead to fatal outcomes. In this report, we describe the case of a patient with excellent performance status prior to pembrolizumab therapy who subsequently suffered myasthenic crisis eventually requiring tracheostomy and long-term mechanical ventilation.
Recommended Citation
Won, Jisun; Zhao, Edward; States, Melissa; Brown, Rachel; El-habr, Abdallah; and Damsker, Jason
(2024)
"Pembrolizumab-induced Myasthenia Gravis and Myocarditis,"
Journal of Community Hospital Internal Medicine Perspectives: Vol. 14:
Iss.
3, Article 17.
DOI: 10.55729/2000-9666.1352
Available at:
https://scholarlycommons.gbmc.org/jchimp/vol14/iss3/17
